John S Bevan, MBChB, MD, FRCP

Aberdeen Royal Infirmary
FP27-1 Potential Predictors of Macroadenoma Volume Reduction After Primary Therapy With Lanreotide Autogel in a Large Treatment-Na´ve Acromegalic Population
OR27-3 High Dose Lanreotide Autogel Treatment Produces Early and Sustained Reductions in Tumor Volume and GH/IGF-1 Levels in Treatment-Na´ve Acromegalic Patients with GH-Secreting Pituitary Macroadenoma: The PRIMARYS Study